A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

NCT02194491 ↗

Phase 1 Completed 18 enrolled Astellas Pharma Global Development, Inc. Yale University · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate a novel PET tracer (\[11C\]AS2471907), and to use \[11C\]AS2471907 to assess the level and time-course of enzyme occupancy in the human brain prior to and following single oral dose administration of ASP3662.

Timeline

Start: 2014-04
Primary completion: 2016-05
Completion: 2016-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	clofutriben	Small molecule	—	Oral

Indications

No indication recorded.